These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32003263)

  • 1. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
    Naderi-Azad S; Sullivan R
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
    [No Abstract]   [Full Text] [Related]  

  • 2. Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Gogas H
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):53-62. PubMed ID: 31903803
    [No Abstract]   [Full Text] [Related]  

  • 3. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline Therapy for
    Pavlick AC; Fecher L; Ascierto PA; Sullivan RJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():564-571. PubMed ID: 31099689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in managing metastatic melanoma: which treatment when?
    Amaral T; Meraz-Torres F; Garbe C
    Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
    Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D
    JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
    Luke JJ
    Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma immunotherapy: strategies to overcome pharmacological resistance.
    Trojaniello C; Vitale MG; Scarpato L; Esposito A; Ascierto PA
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):289-304. PubMed ID: 32195606
    [No Abstract]   [Full Text] [Related]  

  • 12. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
    Hu-Lieskovan S; Robert L; Homet Moreno B; Ribas A
    J Clin Oncol; 2014 Jul; 32(21):2248-54. PubMed ID: 24958825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.
    Tomei S; Wang E; Delogu LG; Marincola FM; Bedognetti D
    Expert Opin Biol Ther; 2014 May; 14(5):663-86. PubMed ID: 24625306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
    Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.